High-dose oral vitamins, minerals do not reduce recurrent cardiac events in heart attack patients

March 12, 2013, American College of Cardiology

Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. However, the results of one component of the NIH-funded Trial to Assess Chelation Therapy (TACT) study, shows that when combined with active chelation therapy, high-dose vitamins and minerals may provide some additional benefit.

The TACT study tested the safety and effectiveness of both EDTA chelation therapy and high-dose vitamin/mineral supplements in individuals with prior heart attacks.

Previous results presented in November 2012 suggested that chelation treatment, with or without supplements, provided a modest reduction in compared to a . These cardiac events were combined and included recurrent , stroke, coronary revascularization, hospitalization for angina and death.

The presentation today focused on the effects of the vitamin/mineral supplements, with or without chelation, compared to caplets, as well as the comparative results of all four study groups (active chelation plus active oral vitamins, active chelation plus placebo oral vitamins, placebo chelation plus active oral vitamins, and placebo chelation plus placebo oral vitamins).

"We did not see a significant benefit of vitamins alone for who had a heart attack," said Gervasio A. (Tony) Lamas, MD, lead author of the study and chief of the Columbia University Division of Cardiology at Mount Sinai Medical Center in Miami Beach, Fla. "Interestingly, patients who received both high dose vitamins and active chelation compared to placebo of both appeared to have additional benefit, but more research is needed to understand the results."

Since 1956, alternative medicine practitioners have used EDTA chelation to treat cardiovascular disease. Chelation therapy involves multiple of a synthetic amino acid called EDTA, which binds to certain minerals and metals, including calcium, lead and cadmium. The study investigators proposed studying chelation and high dose vitamins as separate and combined components to determine potential individual and synergistic effects of the two treatments.

TACT enrolled 1,708 patients with prior heart attacks who were randomly assigned to an active or placebo chelation group and an active or placebo vitamin group. This 2 x 2 factorial design allowed the investigators to clarify the independent contributions of each treatment. Patients received 40 intravenous chelation treatments (or placebo), each lasting about three hours, over about a year and a half.

They were also assigned to take three pills twice daily, which contained either high-dose vitamins and minerals or placebo. Average follow-up was over four years. About half of the patients enrolled in the trial stopped taking the vitamins during the study follow-up; researchers say patient preference was the leading reason, given the number of caplets taken daily.

The primary comparison of the study, oral vitamins and minerals versus an oral placebo, did not show a significant reduction in the primary endpoint: 27 percent in the vitamin group and 30 percent of those receiving, placebo.

The analysis of the four study groups showed that the active/active arm had 108 (26 percent) events and the placebo/placebo arm had 139 (32 percent) events—a statistically significant difference.

The patients in the trial were 82 percent male, 94 percent Caucasian and about half were obese. All had experienced a previous heart attack. Thirty-two percent had diabetes, 68 percent had high blood pressure and 83 percent had previously undergone bypass surgery, stent implantation or balloon angioplasty. Patients were followed for an average of 55 months. The trial was conducted in 134 sites in the United States and Canada from 2002-2011.

Upon entering the study, many patients were already taking evidence-based medications: 84 percent took daily aspirin to reduce risk of stroke and heart attack, 72 percent were on beta-blockers to treat high blood pressure and 73 percent took statins to treat high cholesterol.

Explore further: Study: Mega vitamins won't help after heart attack, chelation treatment might

More information: Dr. Lamas will present "Randomized Comparison of High-dose Oral Vitamins vs. Placebo in the Trial to Assess Chelation Therapy" on Sunday, March 10 at 11:39 a.m., in Moscone Center, South, Esplanade Ballroom.

Related Stories

Study: Mega vitamins won't help after heart attack, chelation treatment might

March 11, 2013
(HealthDay)—There's mixed news from a much-anticipated clinical trial for people who've suffered a heart attack: While a study found that daily high doses of vitamins and minerals did nothing to improve patient outcomes, ...

Alternative therapy produces intriguing results in some heart patients but many questions remain

November 5, 2012
Heart attack  patients given weekly infusions of chemicals used for chelation therapy had fewer cardiovascular events than those who received identical appearing placebo infusions, according to late-breaking clinical trial ...

Chelation therapy doesn't alter quality of life in heart attack patients

November 5, 2012
Chelation therapy didn't change the ability to perform daily tasks or impact the emotional wellbeing of patients who previously suffered a heart attack, according to late-breaking clinical trial research presented at the ...

Recommended for you

Resolvin D-1 limits kidney damage after heart attacks

February 20, 2018
A heart attack triggers an acute inflammatory response at the damaged portion of the heart's left ventricle. If this acute inflammation lingers, it can lead to stretching of the ventricle and heart failure. The inflammation ...

Stroke drug demonstrates safety in clinical trial

February 20, 2018
A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, the most common type of stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug invented at The Scripps ...

Women once considered low risk for heart disease show evidence of previous heart attack scars

February 20, 2018
Women who complain about chest pain often are reassured by their doctors that there is no reason to worry because their angiograms show that the women don't have blockages in the major heart arteries, a primary cause of heart ...

Can your cardiac device be hacked?

February 20, 2018
Medical devices, including cardiovascular implantable electronic devices could be at risk for hacking. In a paper publishing online today in the Journal of the American College of Cardiology, the American College of Cardiology's ...

A drug long used to treat gout may help adult heart failure patients

February 20, 2018
Researchers at the University of Cincinnati (UC) College of Medicine have shown that probenecid, a drug long used to treat gout, may be able to improve heart function in adult patients who experience heart failure.

Number of obese years not—just obesity—a distinct risk factor for heart damage

February 20, 2018
In an analysis of clinical data collected on more than 9,000 people, Johns Hopkins researchers have shown that the number of years spent overweight or obese appear to "add up" to a distinct risk factor that makes those with ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.